264 related articles for article (PubMed ID: 15644400)
21. Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers.
Leaf DE; Korets R; Taylor EN; Tang J; Asplin JR; Goldfarb DS; Gupta M; Curhan GC
Clin J Am Soc Nephrol; 2012 May; 7(5):829-34. PubMed ID: 22422535
[TBL] [Abstract][Full Text] [Related]
22. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data.
Diamond TH; Ho KW; Rohl PG; Meerkin M
Med J Aust; 2005 Jul; 183(1):10-2. PubMed ID: 15992330
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D-binding protein levels do not influence the effect of vitamin D repletion on serum PTH and calcium: data from a randomized, controlled trial.
Ponda MP; McGee D; Breslow JL
J Clin Endocrinol Metab; 2014 Jul; 99(7):2494-9. PubMed ID: 24712573
[TBL] [Abstract][Full Text] [Related]
24. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study.
Molina P; Górriz JL; Molina MD; Peris A; Beltrán S; Kanter J; Escudero V; Romero R; Pallardó LM
Nephrol Dial Transplant; 2014 Jan; 29(1):97-109. PubMed ID: 23975842
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of vitamin D deficiency in primary hyperparathyroidism, and safety of vitamin D therapy.
Mikhail N
South Med J; 2011 Jan; 104(1):29-33. PubMed ID: 21079532
[TBL] [Abstract][Full Text] [Related]
26. Markers of bone remodeling in the elderly subject: effects of vitamin D insufficiency and its correction.
Brazier M; Kamel S; Maamer M; Agbomson F; Elesper I; Garabedian M; Desmet G; Sebert JL
J Bone Miner Res; 1995 Nov; 10(11):1753-61. PubMed ID: 8592953
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D and primary hyperparathyroidism (PHPT).
Souberbielle JC; Bienaimé F; Cavalier E; Cormier C
Ann Endocrinol (Paris); 2012 Jun; 73(3):165-9. PubMed ID: 22677209
[TBL] [Abstract][Full Text] [Related]
28. An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1-infected women independently of protease inhibitors therapy: a pilot study.
Pepe J; Mezzaroma I; Fantauzzi A; Falciano M; Salotti A; Di Traglia M; Diacinti D; Biondi P; Cipriani C; Cilli M; Minisola S
Endocrine; 2016 Jul; 53(1):299-304. PubMed ID: 26254790
[TBL] [Abstract][Full Text] [Related]
29. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis.
Sahota O; Mundey MK; San P; Godber IM; Lawson N; Hosking DJ
Bone; 2004 Jul; 35(1):312-9. PubMed ID: 15207772
[TBL] [Abstract][Full Text] [Related]
30. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
[TBL] [Abstract][Full Text] [Related]
31. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
32. Pilot Study Evaluating Efficacy of 2 Regimens for Hypovitaminosis D Repletion in Pediatric Inflammatory Bowel Disease.
Simek RZ; Prince J; Syed S; Sauer CG; Martineau B; Hofmekler T; Freeman AJ; Kumar A; McElhanon BO; Schoen BT; Tenjarla G; McCracken C; Ziegler TR; Tangpricha V; Kugathasan S
J Pediatr Gastroenterol Nutr; 2016 Feb; 62(2):252-8. PubMed ID: 26196201
[TBL] [Abstract][Full Text] [Related]
33. Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults.
Olmos JM; Hernández JL; García-Velasco P; Martínez J; Llorca J; González-Macías J
Osteoporos Int; 2016 Jan; 27(1):105-13. PubMed ID: 26134682
[TBL] [Abstract][Full Text] [Related]
34. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers.
Farahnak P; Lärfars G; Sten-Linder M; Nilsson IL
J Clin Endocrinol Metab; 2011 Jul; 96(7):2112-8. PubMed ID: 21593116
[TBL] [Abstract][Full Text] [Related]
35. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
36. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism.
Silverberg SJ; Shane E; Dempster DW; Bilezikian JP
Am J Med; 1999 Dec; 107(6):561-7. PubMed ID: 10625024
[TBL] [Abstract][Full Text] [Related]
37. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Jansson S; Morgan E
World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486
[TBL] [Abstract][Full Text] [Related]
38. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease.
Valdemarsson S; Lindergård B; Tibblin S; Bergenfelz A
J Intern Med; 1998 Feb; 243(2):115-22. PubMed ID: 9566639
[TBL] [Abstract][Full Text] [Related]
39. Seasonal Variability in Vitamin D Levels No Longer Detectable in Primary Hyperparathyroidism.
Cong E; Walker MD; Kepley A; Zhang C; McMahon DJ; Silverberg SJ
J Clin Endocrinol Metab; 2015 Sep; 100(9):3452-9. PubMed ID: 26120793
[TBL] [Abstract][Full Text] [Related]
40. Suppression by calcium of serum levels of intact parathyroid hormone in patients with primary hyperparathyroidism.
Bergenfelz A; Valdermarsson S; Ahrén B
Horm Res; 1993; 39(3-4):146-51. PubMed ID: 8262476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
